Axial

Share this post
Axial - Cipher #5 (gene therapy)
axial.substack.com

Axial - Cipher #5 (gene therapy)

Finding the other half

Joshua Elkington
Aug 8, 2019
Comment
Share

Analysis of public clinical and business development data in life sciences.

Gene therapies have been on a rollercoaster over the last few decades:

With Spark Therapeutics getting the first AAV approval and Bluebird Bio, uniQure, AveXis doing incredible work. The average gene therapy deal value peaked around $200M with the number of partnerships seeing a marked rise in early 2010:

With a focus on research and licensing agreements:

Focused on discovery and foundation work:

With deals having no geographic preference:

Thank you.

CommentComment
ShareShare

Create your profile

0 subscriptions will be displayed on your profile (edit)

Skip for now

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.

TopNewCommunity

No posts

Ready for more?

© 2022 Axial
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing